US 12,281,118 B2
Nitrogen-containing fused heterocyclic SHP2 inhibitor compound, preparation method, and use
Huixin Wan, Nantong (CN); Jianfeng Pan, Nantong (CN); Jingui Ma, Nantong (CN); and Chuantao Cha, Nantong (CN)
Assigned to SHANGHAI RINGENE BIOPHARMA CO., LTD., Shanghai (CN)
Appl. No. 17/292,027
Filed by SHANGHAI RINGENE BIOPHARMA CO., LTD., Shanghai (CN)
PCT Filed Nov. 7, 2019, PCT No. PCT/CN2019/116386
§ 371(c)(1), (2) Date May 7, 2021,
PCT Pub. No. WO2020/094104, PCT Pub. Date May 14, 2020.
Claims priority of application No. 201811317588.8 (CN), filed on Nov. 7, 2018; application No. 201811594644.2 (CN), filed on Dec. 26, 2018; and application No. 201910131491.6 (CN), filed on Feb. 22, 2019.
Prior Publication US 2022/0127271 A1, Apr. 28, 2022
Int. Cl. A23K 50/10 (2016.01); A23K 20/158 (2016.01); A61K 9/00 (2006.01); A61P 35/02 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07D 519/00 (2006.01); C07K 16/28 (2006.01)
CPC C07D 487/04 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61P 35/02 (2018.01); C07D 471/04 (2013.01); C07D 519/00 (2013.01); C07K 16/2827 (2013.01)] 6 Claims
 
1. A nitrogen-containing fused heterocyclic compound, a pharmaceutically acceptable salt thereof, an enantiomer thereof, a diastereomer thereof, a tautomer thereof, a solvate thereof, a polymorph thereof or a prodrug:

OG Complex Work Unit Chemistry